New migraine treatments have brought stunning relief to many people by blocking the action of calcitonin gene-related peptide (CGRP), a protein in the brain involved in the migraine process.

Discover the latest breakthroughs in migraine treatment for 2025, including CGRP inhibitors, AI-powered personalized plans, ...

A groundbreaking study has uncovered new insights into the pain pathways associated with temporomandibular joint (TMJ) ...

The following is a summary of “Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 ...

Research reveals howneurogenic connection can directly trigger inflammatory processes, creating pain patterns that challenge ...

The CGRP inhibitors have performed well in clinical trials, but so far commercial success has been limited, despite blockbuster sales predictions ahead of their approval.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

One chemical -- called CGRP -- is thought to play a major role in worsening migraines and prolonging their effects. CGRP causes blood vessels to dilate and triggers additional inflammation ...